Tim Barder is a Senior Consultant with Cutter Consortium's Business Technology & Digital Transformation Strategies practice and Principal at Arthur D. Little, Boston, and focuses on generating and delivering actionable strategic insights and tangible results to clients across multiple industries. He has significant expertise in end-to-end innovation with quantifying consumer needs to product launch; analytical-driven market, technology, and competitive assessments; and economic and environmental lifecycle analyses. Previously, Mr. Barder led drug discovery and development programs at Vertex Pharmaceuticals and Merck Research Labs.
Tim conducted post-doctoral research under the late 2008 Nobel Laureate Professor Roger Tsien in the field of tumor targeting, and graduate research under Professor Stephen Buchwald in the fields of organic methodology and mechanistic chemistry. He received a PhD in organic chemistry from the Massachusetts Institute of Technology. His undergraduate degree is in chemistry from University of California, San Diego. Tim is a co-author on over 20 peer-reviewed publications and patents, which have garnered nearly 5,000 citations to date. He can be reached at firstname.lastname@example.org.